The Perthera Analysis provides precisely matched therapeutic options ranked for the best probability of best outcome.
The Perthera Analysis recommends clinical trials and treatments specific to each patient’s cancer to give physicians the supportive information needed to treat their patients.
Perthera Precision Medicine is cost-effective and eliminates the operational challenges typically associated with precision medicine projects.
Every cancer is unique, and Perthera is committed to providing the best treatment options specific to each patient for a greater likelihood of an improved outcome.
Gary Gregory is a skilled and experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the Healthcare Sector. His experience spans numerous companies and positions including Executive Officer roles across successful start-up companies (Neuronix, Advanced Dx, NeuroMetrix, PrimeSource Healthcare), and leadership roles in Fortune 250 companies (Johnson & Johnson, Baxter, and Kendall Healthcare).
Gary has also served in Board roles from Chairman, Director, and Advisor to numerous organizations. He is recognized as a proven executive leader with big company capabilities and a start-up company mindset.
Gary has grown Perthera to be a proven, scaled business throughout the United States. Perthera is a market leading Precision Oncology Informatics Company proven to improve patient outcomes – while capturing & delivering the world’s most comprehensive cancer data, tissue & services – to transform Precision Oncology for Physicians, Suppliers, Biopharma & Patients.
Gary holds a B.S. in Economics and Minor in Business Administration from Pennsylvania State University.